Penile cancer

Researchers are testing a vaccine called BNT113 in people whose cancers are driven by HPV16, a common virus linked to head and neck, cervical, and anogenital tumors. The trial enrolls two groups: one with head and neck cancer that has been treated and shows no signs of disease, a…

This study tests an HPV vaccine (PRGN-2009) alone or with a drug called M7824 in people with HPV-positive cancers like cervical, anal, and throat cancers. The goal is to find a safe dose and see if the combination boosts the immune system's attack on tumors. The trial includes 39…

This early-stage trial is testing a combination of two lab-made antibodies in people with advanced solid tumors that have not responded to standard treatments. One antibody (LDP) aims to reactivate the immune system against cancer, while the other (CDP1) blocks a growth signal on…

This study tests a combination of three immunotherapy drugs—PDS0101, M7824, and NHS-IL12—in people with advanced HPV-related cancers such as cervical, anal, and throat cancers. The goal is to see if the mix can shrink tumors or stop them from growing. Participants receive the dru…

This trial tested a new therapy for cancers caused by HPV-16, such as cervical, anal, and throat cancers. Researchers took patients' white blood cells, genetically engineered them to recognize a protein called E7 found in HPV cancer cells, and infused them back. Patients also rec…

This trial tests whether a new hybrid tracer, ICG-99mTc-nanoscan, can replace the standard tracer for sentinel node biopsy in people with penile cancer, melanoma, or oral cancer. The hybrid tracer combines a fluorescent dye with a radioactive marker, potentially allowing surgeons…

This study looks at whether a blood test that detects tumor DNA can find early signs of cancer returning in people treated for HPV-positive pelvic cancers (like cervical or anal cancer). Researchers will take blood samples from 172 patients during regular follow-up visits. The go…